SI2307409T1 - Pirolopiridini kot kinazni inhibitorji - Google Patents

Pirolopiridini kot kinazni inhibitorji

Info

Publication number
SI2307409T1
SI2307409T1 SI200931284T SI200931284T SI2307409T1 SI 2307409 T1 SI2307409 T1 SI 2307409T1 SI 200931284 T SI200931284 T SI 200931284T SI 200931284 T SI200931284 T SI 200931284T SI 2307409 T1 SI2307409 T1 SI 2307409T1
Authority
SI
Slovenia
Prior art keywords
pyrrolopyridines
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
SI200931284T
Other languages
English (en)
Inventor
Huerou Yvan Le
James F. Blake
Indrani W. Gunwardana
Peter J. Mohr
Eli M. Wallace
Bin Wang
Mark Chicarelli
Michael Lyon
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2307409(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of SI2307409T1 publication Critical patent/SI2307409T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200931284T 2008-05-13 2009-05-13 Pirolopiridini kot kinazni inhibitorji SI2307409T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5292608P 2008-05-13 2008-05-13
EP09747404.3A EP2307409B1 (en) 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors
PCT/US2009/043691 WO2009140320A1 (en) 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
SI2307409T1 true SI2307409T1 (sl) 2015-11-30

Family

ID=40810786

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931284T SI2307409T1 (sl) 2008-05-13 2009-05-13 Pirolopiridini kot kinazni inhibitorji

Country Status (30)

Country Link
US (6) US8178131B2 (sl)
EP (2) EP2307409B1 (sl)
JP (2) JP5703212B2 (sl)
KR (2) KR101657856B1 (sl)
CN (3) CN104926810B (sl)
AR (1) AR071717A1 (sl)
AU (1) AU2009246402B2 (sl)
BR (1) BRPI0913580B8 (sl)
CA (1) CA2724262C (sl)
CL (1) CL2009001152A1 (sl)
CO (1) CO6321244A2 (sl)
CR (1) CR11803A (sl)
CY (1) CY1116692T1 (sl)
DK (1) DK2307409T3 (sl)
ES (1) ES2552643T3 (sl)
HK (2) HK1152035A1 (sl)
HR (1) HRP20151018T1 (sl)
HU (1) HUE026160T2 (sl)
IL (1) IL209258A (sl)
MX (1) MX2010012449A (sl)
NZ (1) NZ589318A (sl)
PH (1) PH12013501779B1 (sl)
PL (1) PL2307409T3 (sl)
PT (1) PT2307409E (sl)
RS (1) RS54358B1 (sl)
RU (1) RU2517194C2 (sl)
SI (1) SI2307409T1 (sl)
TW (2) TWI458727B (sl)
UA (1) UA111933C2 (sl)
WO (1) WO2009140320A1 (sl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2242755B1 (en) 2008-01-08 2012-09-12 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
US8372842B2 (en) 2008-01-09 2013-02-12 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
CN102612365B (zh) * 2009-04-11 2017-04-12 阵列生物制药公司 用于强化dna损伤剂的检查点激酶1抑制剂
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2485589A4 (en) * 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYARY INHIBITORS OF BTK
CA2808543C (en) 2010-08-20 2016-01-26 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
KR101884960B1 (ko) * 2010-11-16 2018-08-30 어레이 바이오파마 인크. 체크포인트 키나제 1 억제제 및 wee 1 키나제 억제제의 조합
EP2678329B1 (en) 2011-02-25 2015-11-18 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
WO2012148775A1 (en) 2011-04-29 2012-11-01 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
KR102096679B1 (ko) 2012-04-23 2020-04-02 제넨테크, 인크. 화합물의 제조를 위한 중간체 및 방법
EP3024457A4 (en) 2013-07-26 2017-06-28 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
CN105705499B (zh) * 2013-08-22 2018-10-12 基因泰克公司 用于制备化合物的方法
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
ES2785053T3 (es) * 2013-09-25 2020-10-05 Vertex Pharma Un inhibidor selectivo de fosfatidilinositol 3-quinasa-gamma
KR102456088B1 (ko) 2014-04-04 2022-10-19 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
TW201613919A (en) 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
CN107708414B (zh) 2015-06-30 2022-02-25 首尔伟傲世有限公司 适用紫外线发光二极管的捕虫器
EP4014977A1 (en) * 2015-11-04 2022-06-22 Merck Patent GmbH Pyrimidine compounds with btk inhibitory activity for use in treating cancer
BR112018012707A2 (pt) * 2015-12-22 2019-01-29 Vitae Pharmaceuticals Inc inibidores da interação de menin-mll
PL3468966T3 (pl) 2016-06-10 2021-04-06 Vitae Pharmaceuticals, Llc Inhibitory interakcji menina-mll
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
WO2020010092A1 (en) 2018-07-03 2020-01-09 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US20230271941A1 (en) 2020-07-15 2023-08-31 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2024517945A (ja) 2021-05-14 2024-04-23 シンダックス ファーマシューティカルズ， インコーポレイテッド メニン－ｍｌｌ相互作用の阻害剤

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU689809B2 (en) * 1993-10-14 1998-04-09 Abbott Laboratories Quinolizinone type compounds
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US6653304B2 (en) 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
WO2001079198A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US6797825B2 (en) * 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
JP2005534713A (ja) 2002-08-07 2005-11-17 三菱ウェルファーマ株式会社 ジヒドロピラゾロピリジン化合物
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
BRPI0408256A (pt) 2003-03-14 2006-03-01 Astrazeneca Ab composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
TW200604168A (en) * 2004-04-02 2006-02-01 Vertex Pharma Azaindoles useful as inhibitors of rock and other protein kinases
AU2005244745B2 (en) * 2004-04-13 2012-05-03 Synta Pharmaceuticals Corp. Disalt inhibitors of IL-12 production
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
MX2007012448A (es) 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
EP2354140A1 (en) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
KR101149954B1 (ko) * 2005-08-30 2012-06-01 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물
NZ567151A (en) * 2005-10-06 2012-03-30 Schering Corp Pyrazolo [1,5 -A] pyrimidine derivatives and their use for inhibiting Checkpoint kinases
AR056206A1 (es) 2005-10-06 2007-09-26 Schering Corp Pirazolpirimidinas como inhibidores de protein quinasas
ES2611588T3 (es) 2005-12-13 2017-05-09 Incyte Holdings Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
EP3421471B1 (en) 2006-04-25 2021-05-26 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
JP2009536161A (ja) 2006-04-25 2009-10-08 アステックス、セラピューティックス、リミテッド 医薬化合物
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
US8822497B2 (en) 2007-03-01 2014-09-02 Novartis Ag PIM kinase inhibitors and methods of their use
WO2009004329A1 (en) * 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
MX2010005095A (es) 2007-11-07 2010-08-03 Schering Corp Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion.
EP2242755B1 (en) * 2008-01-08 2012-09-12 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
US8372842B2 (en) * 2008-01-09 2013-02-12 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US20140221370A1 (en) 2010-07-09 2014-08-07 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
KR101884960B1 (ko) 2010-11-16 2018-08-30 어레이 바이오파마 인크. 체크포인트 키나제 1 억제제 및 wee 1 키나제 억제제의 조합

Also Published As

Publication number Publication date
TW201002707A (en) 2010-01-16
TW201529573A (zh) 2015-08-01
HK1152035A1 (en) 2012-02-17
EP2307409B1 (en) 2015-08-12
DK2307409T3 (en) 2015-09-21
EP2307409A1 (en) 2011-04-13
CR11803A (es) 2011-02-11
AR071717A1 (es) 2010-07-07
HUE026160T2 (en) 2016-05-30
US20140243520A1 (en) 2014-08-28
UA111933C2 (uk) 2016-07-11
CA2724262A1 (en) 2009-11-19
US20160368916A1 (en) 2016-12-22
NZ589318A (en) 2011-06-30
MX2010012449A (es) 2011-05-25
PH12013501779A1 (en) 2014-08-27
PL2307409T3 (pl) 2016-01-29
JP5703212B2 (ja) 2015-04-15
EP2990407A1 (en) 2016-03-02
KR20110008102A (ko) 2011-01-25
IL209258A0 (en) 2011-01-31
HK1219950A1 (zh) 2017-04-21
CY1116692T1 (el) 2017-03-15
BRPI0913580B1 (pt) 2020-03-10
WO2009140320A1 (en) 2009-11-19
US20150322061A1 (en) 2015-11-12
CO6321244A2 (es) 2011-09-20
CN104926810B (zh) 2019-02-19
KR101643426B1 (ko) 2016-07-27
RU2010150786A (ru) 2012-06-20
BRPI0913580B8 (pt) 2021-05-25
IL209258A (en) 2017-01-31
CN102089307B (zh) 2015-07-01
AU2009246402B2 (en) 2013-05-23
TWI458727B (zh) 2014-11-01
CA2724262C (en) 2017-08-15
US20110070317A1 (en) 2011-03-24
CN104926810A (zh) 2015-09-23
RU2517194C2 (ru) 2014-05-27
TWI554512B (zh) 2016-10-21
KR20140093266A (ko) 2014-07-25
JP2011520896A (ja) 2011-07-21
US20130045286A1 (en) 2013-02-21
KR101657856B1 (ko) 2016-09-19
US9365568B2 (en) 2016-06-14
RS54358B1 (en) 2016-04-28
US20140100369A1 (en) 2014-04-10
JP2015098482A (ja) 2015-05-28
ES2552643T3 (es) 2015-12-01
HRP20151018T1 (hr) 2015-10-23
US9969727B2 (en) 2018-05-15
US8758830B2 (en) 2014-06-24
BRPI0913580A2 (pt) 2015-10-20
US8545897B2 (en) 2013-10-01
AU2009246402A1 (en) 2009-11-19
US8178131B2 (en) 2012-05-15
EP2990407B1 (en) 2019-10-16
PH12013501779B1 (en) 2014-08-27
CN109942575A (zh) 2019-06-28
US8981085B2 (en) 2015-03-17
PT2307409E (pt) 2015-11-04
CL2009001152A1 (es) 2009-10-16
CN102089307A (zh) 2011-06-08

Similar Documents

Publication Publication Date Title
HK1219950A1 (zh) 作爲激酶抑制劑的吡咯並吡啶
HUS1900029I1 (hu) Kináz inhibitor foszforszármazékok
HK1156026A1 (en) Pyrazolopyridine kinase inhibitors
HRP20130787T1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
HRP20130698T1 (en) Novel phenylpyrazinones as kinase inhibitors
HK1179477A1 (en) Kinase inhibitors
IL206358A0 (en) Pyrrolopyrazine kinase inhibitors
ZA201203842B (en) Kinase inhibitors
SI2334677T1 (sl) Triazolopiridinske spojine kot inhibitorji PIM kinaze
EP2558099A4 (en) Kinase Inhibitors
IL210573A0 (en) Compounds as kinase inhibitors
PT2231642E (pt) Pirimidinas como inibidores de quinase
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
EP2231152A4 (en) THIENOPYRANONES AS KINASE INHIBITORS
EP2480076A4 (en) IMIDAZOTHIAZOLIC INHIBITORS OF KINASES
GB0914726D0 (en) Kinase inhibitors
ZA201004903B (en) Pyrrolopyrazine kinase inhibitors